Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01247571 · FLOW

Participant flow

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
    id
    FG000
    title
    Pazopanib
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        22
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        3
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
    id
    FG000
    title
    Pazopanib
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        22
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        3
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice